PHC Holdings 6523.T · JPY

Its shares trade on Tokyo Stock Exchange under the ticker 6523.T. It has been listed since 14 October 2021. In the fiscal year to 31 March 2026, it reported revenue of ¥364.40bn and net income of ¥492.0m. At that date it held total assets of ¥542.51bn and shareholders' equity of ¥161.67bn.

PHC Holdings Corp. engages in the development, manufacture, and sale of healthcare devices and services. The company is headquartered in Minato-Ku, Tokyo-To. The company went IPO on 2021-10-14. The firm operates through three business segments. The Diabetes Management segment is involved in the development, manufacture and sale of in vitro diagnostic equipment such as self-monitoring blood glucose systems and point-of-care testing (POCT) products and electric drug injectors. The Healthcare Solutions segment is involved in the development and sale of medical information technology (IT) products such as receipt computers and electronic medical records, as well as the development of clinical laboratory diagnosis business. The Diagnostic and Life Science segment is involved in the development, manufacture and sale of research and medical support equipment, pathological diagnosis equipment, among others.

Figures and description from our data supplier, not checked against the company's own report.

• Ms. Kyoko DeguchiPresident, Chief Executive Officer, Representative Director, since 2021¥149.0m
• Mr. Kaiju YamaguchiSenior Managing Executive Officer, Chief Financial Officer, Director, since 2022
• Mr. Koichiro SatoVice President, Chief Operating Officer, Chief Strategy Officer, Manager of Diabetes Management Domain, Manager of Healthcare Solutions Domain, Director of BGM Business, Representative Director, since 2017
• Mr. Ryuichi HirashimaSenior Managing Executive Officer, Chief Human Resources Officer, Chief Administrative Officer, Chief Transformation Officer
• Mr. Nobuaki NakamuraManaging Executive Officer, Manager of Diagnostics and Life Sciences Domain
• Mr. Steven LynumExecutive Officer, Assistant Manager of Diagnostics and Life Sciences Domain, Director of Pathology Business
• Mr. Hideaki TakahashiExecutive Officer, Director of Healthcare IT Solution Business
• Mr. Chikara TakauoExecutive Officer, Director of Biomedical Business
• Mr. Kenichi UchinoExecutive Officer, Director of LSIM Business
• Mr. Hirofumi HiranoIndependent Director
• Mr. David SneiderIndependent Director
• Mr. Ivan TornosIndependent Director

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.